1. Medtech Insight
  2. >>Device Area
  3. >>Diabetic Care

Dexcom Promotes CGM As First-Line Tool In Type 2 Diabetes

Company Combines Education, Advocacy And Clinical Studies To Shift Standard Of Treatment.

 
• By Shubham Singh

Only 14% of people with type 2 diabetes use continuous glucose monitors, although 93% of users report a positive impact on their health. Dexcom is ramping up efforts to close this adoption gap.

One of the most significant is the Steno2Tech study, a 12-month, single-center, randomized controlled trial conducted at the Steno Diabetes Center, Copenhagen, Denmark
Key Takeaways
  • Dexcom’s multiple clinical studies, include pivotal Steno2Tech trial, to position CGM as a first-line tool in type 2 diabetes. 

      Dexcom is ramping up efforts to increase adoption of continuous glucose monitoring (CGM) among people with type 2 diabetes through...

      More from Diabetic Care

      More from Medtech Insight